This is a retrospective study analyzing the impact of additional cytogenetic abnormalities and gene mutations (myeloid gene, MDS-related genes and KRAS/NRAS genes) in patients with NPM1-mutated and/or FLT3-ITD mutated AML, treated with intensive chemotherapy and FLT3 inhibitors, as appropriate. This evidence concerns the gene NPM1 and myelodysplastic syndrome.